In HR (+)/HER2 (‐) breast cancers, increased expression of FGFR1 was found in hormone‐resistant breast cancer and in patients who received CDK4/6 inhibitors, and these patients can receive 19% of the objective response rate (ORR) treated by lucitanib.39, 40. Here, ERBB2 is linked to breast carcinoma.